Combining computational and experimental biology to develop therapeutically valuable IL2 muteins

High dose IL2 first approved in 1992, has been used in the treatment of advanced renal cell carcinoma and melanoma. In these indications, IL2 induces long lasting objective responses in 5 to 20% of the patients. But, its toxicity and the unexpected expansion of regulatory T cells (Tregs) have limited its practical use and therapeutic impact respectively. At the Center of Molecular Immunology in Havana, Cuba, a project was launched in 2005 to rationally design IL2 muteins that could be deployed in the therapy of cancer.
Source: Seminars in Oncology - Category: Cancer & Oncology Authors: Source Type: research